Blog
RSS FeedPosted by Michael Wonder on 06 Jul 2018
Decision to widen access and change the funded enzyme replacement therapy for Gaucher disease
6 Jul 2018 - PHARMAC is pleased to announce changes to the funding of enzyme replacement therapy used in the ...
Posted by Michael Wonder on 08 Jun 2018
Decision to fund denosumab for osteoporosis
8 June 2018 - PHARMAC is pleased to announce a decision to fund denosumab (Prolia) for the treatment of severe, ...
Posted by Michael Wonder on 14 May 2018
Decision to widen access and change the funded brand of tenofovir disoproxil and entecavir
14 May 2018 - PHARMAC is pleased to announce decisions to approve agreements with Teva Pharma New Zealand Limited and ...
Posted by Michael Wonder on 12 May 2018
Decision to fund mercaptopurine oral suspension
10 May 2018 - PHARMAC is pleased to announce the approval of an agreement with Link Pharmaceuticals Limited for the ...
Posted by Michael Wonder on 04 May 2018
Decision to fund aflibercept and rivaroxaban
3 May 2018 - PHARMAC is pleased to announce the approval of an agreement with Bayer New Zealand Limited for ...
Posted by Michael Wonder on 03 Apr 2018
Relief for sufferers of neuroendocrine cancer after PHARMAC funding decision
1 April 2018 - Kiwis living with neuroendocrine cancer say they are relieved after PHARMAC recommended their treatment should be ...
Posted by Michael Wonder on 29 Mar 2018
Decision to list eplerenone for the treatment of heart failure
29 March 2018 - PHARMAC is pleased to announce a decision to fund eplerenone (Inspra), subject to certain clinical criteria ...
Posted by Michael Wonder on 07 Mar 2018
Decision to change the funded brand of aripiprazole and remove listing restrictions
7 March 2018 - PHARMAC is pleased to announce the approval of an agreement with Novartis New Zealand Limited for ...
Posted by Michael Wonder on 07 Feb 2018
No political pressure in HIV drug funding call - PHARMAC
7 February 2018 - PHARMAC is rejecting any suggestion it reacted to political pressure to fund a new anti-HIV drug. ...
Posted by Michael Wonder on 07 Feb 2018
PHARMAC widening access to Truvada for the prevention of HIV infection
7 February 2018 - Decision means Truvada will be funded for pre-exposure prophylaxis in New Zealand before Australia. ...
Posted by Michael Wonder on 12 Jan 2018
Decision to widen access to pulmonary arterial hypertension treatments
12 January 2018 - PHARMAC is pleased to announce our decision to widen funded access to five treatments for pulmonary ...
Posted by Michael Wonder on 20 Dec 2017
Decision to fund cetuximab for head and neck cancer
20 December 2017 - PHARMAC is pleased to announce our decision to fund cetuximab (Erbitux) from 1 February 2018 for ...
Posted by Michael Wonder on 14 Dec 2017
Up to 3,000 women to benefit from PHARMAC decision
14 December 2017 - Post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to ...
Posted by Michael Wonder on 12 Dec 2017
Decision to widen access to various anti-infectives
12 December 2017 - PHARMAC is pleased to announce our decision to widen funded access to three treatments: ...
Posted by Michael Wonder on 08 Dec 2017
Decision to fund methylnaltrexone in palliative care
8 December 2017 - PHARMAC is pleased to announce the approval of an agreement with Link Pharmaceuticals Limited for the ...